betuvaxameran

Betuvaxameran (VidPrevtyn Beta) is a monovalent, recombinant protein subunit COVID-19 vaccine co-developed by Sanofi and GSK. It consists of a stabilized prefusion SARS-CoV-2 spike protein antigen derived from the B.1.351 (Beta) variant, produced using Sanofi's proprietary Baculovirus Expression Vector System (BEVS) in insect cells. The vaccine is adjuvanted with GSK's proprietary AS03, an oil-in-water emulsion containing squalene, DL-α-tocopherol, and polysorbate-80, which enhances the immune response. It is primarily indicated as a booster dose for the prevention of COVID-19 in adults who have previously received mRNA or adenoviral vector vaccines. The vaccine aims to elicit neutralizing antibody responses against the Beta variant and provide cross-reactive protection against other variants of concern. It received marketing authorization in the European Union and the United Kingdom in November 2022. In clinical research, such as the NIAID-sponsored ACV01 trial, it has been evaluated for its ability to boost immune responses in specific populations, including patients with autoimmune diseases on immunosuppressive therapy.

Brand names

VidPrevtyn Beta

Other names

monovalent [B.1.351] CoV2 preS dTM-AS03Sanofi-GSK Beta vaccineSARS-CoV-2 (B.1.351) recombinant spike protein vaccine